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0.610 for typical adherence, and 0.441 for ideal adherence.
Mean life expectancy was 14.73 years for no treatment, 15.07
years for typical adherence, and 15.49 for ideal adherence. The
incremental cost effectiveness ratio per life-year gained was
$30,585 between typical adherence and no treatment, and
$22,121 between ideal adherence and typical adherence. CON-
CLUSION: Nonadherence to lipid-lowering and antihyperten-
sive therapy contributes signiﬁcantly to the clinical and economic
burden of heart disease and stroke in the population considered.
Patients with typical adherence levels receive approximately
50% of the risk reduction seen in clinical trials with controlled
levels of ideal adherence.
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OBJECTIVES: To determine the cost-effectiveness of providing
aspirin, low molecular weight heparin (LMWH), or compression
stockings to air travelers for the prevention of air traveler throm-
bosis (ATT). METHODS: A pharmacoeconomic model was con-
structed from the perspective of a 1.5 million member US
managed care organization (MCO). The model had a one-year
time horizon to coincide with typical budgetary cycles. Air travel
estimates were calculated using 2005 Federal Aviation Adminis-
tration and US Census Bureau statistics. Published ATT inci-
dence estimates varied across patient risk factors and distance
ﬂown, ranging from zero to 455 events per 100,000 ﬂights.
Treatment efﬁcacy estimates for the relative risk reduction of
ATT during and immediately following air travel were obtained
from published literature. The model assumed prophylactic
therapy use prior to each ﬂight; for compression stockings, one
set was issued per patient for all ﬂights. Cost inputs included
medical charges for incident ATT treatment (extrapolated from
the literature) and prophylactic treatments (estimated from
wholesale acquisition costs). Five reiterations of the model were
performed to test all ATT incidence estimates. Incremental cost-
effectiveness ratios (ICERs) were calculated for prophylaxis
versus no treatment. RESULTS: In 4 of 5 risk scenarios, ICERs
for aspirin prophylaxis was dominant, with potential MCO cost
savings ranging from $436,700 to $1,251,500. For compression
stockings, ICERs were dominant for patients taking long-haul
ﬂights only (>5000 miles), with potential cost savings of
$957,700 to $1,141,600. LMWH prophylaxis did not result in
cost savings under any scenario. Reducing the treatment efﬁcacy
estimates by up to 20% did not alter these results. CONCLU-
SION: Payment for prophylactic aspirin therapy for ATT pre-
vention in air travelers resulted in cost savings for a MCO, as
did payment for compression stockings for use during long-haul
ﬂights. MCOs that develop programs to provide prophylactic
therapies to air travelers could realize signiﬁcant cost savings.
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OBJECTIVES: Pharmacoeconomic analysis of extended pre-
ventive injection of enoxaparin after hip joint replacement 
and costing of one prevented case of deep venous thrombosis
(DVT) in the enoxaparin group compared to placebo in Russia.
METHODS: The pharmacoeconomic analysis was based on the
results of prospective, randomized, double controlled study of
the use of enoxaparin as extended DVT prophylaxis conducted
in a clinical center in Sweden (Bergqvist D. et al., 1996). The efﬁ-
ciency of extended prophylaxis by enoxaparin versus placebo in
hospital environment was studied during the trial. All patients
(n = 262) received a daily hypodermic injection of 40 mg of
enoxaparin after preventative hip joint replacement, on average
during 9 days of their hospitalization (open study period). After
that the patients were randomized in groups. 131 patients in the
placebo group and 131 patients in the enoxaparin group received
the treatment. It was suggested that the patients of both groups
be injected with 40 mg of enoxaparin daily, on average during
18.6 days. In the clinical trial the number of detected DVT in
each group was assumed as the most adequate index of efﬁciency.
21 and 45 DVT cases were detected in the enoxaparin and the
placebo group respectively. RESULTS: In Russia total costs of
extended prophylaxis after hip joint replacement in comparison
groups amounted to $186,272 in the enoxaparin group and
$159,584 in the placebo group. Costs per patient amounted to
$1422 in the enoxaparin group and to $1218 in the placebo
group. With the help of efﬁciency increment analysis, the cost of
one DVT case prevented by way of extended prophylaxis by
enoxaparin versus placebo amounted to $1112. CONCLU-
SION: According to the results of the pharmacoeconomic analy-
sis based on the ﬁndings of the clinical trial, the cost of one DVT
case prevented with the help of extended prophylaxis by enoxa-
parin versus placebo is $1112.
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OBJECTIVES: Given the changing statin marketplace, this study
compares the cost-effectiveness among generic statins (lovas-
tatin, pravastatin, simvastatin) and more effective branded
monotherapy statins (atorvastatin, rosuvastatin) for ﬁrst and
second tier placement consideration, respectively, in routine clin-
ical practice. METHODS: Retrospective electronic medical
record database study was conducted of newly prescribed statin
therapy during August 2003–March 2005. Effectiveness of each
statin in reducing LDL-C and attaining National Cholesterol
Education Panel Adult Treatment Panel III LDL-C goal was eval-
uated using multivariate regressions after adjusting for baseline
LDL-C, demographics, comorbidities, and therapy duration.
Cost-effectiveness from a payer perspective was estimated for
rosuvastatin and atorvastatin (branded statins), and separately
for lovastatin, simvastatin and pravastatin (generic statins).
Annualized costs for statin (wholesale acquisition cost, WAC)
and titration were included. RESULTS: Of 10,421 eligible
patients, adjusted LDL-C reduction was signiﬁcantly greater (p
< 0.001) with rosuvastatin (−31.6%) than atorvastatin (−21.9%)
and other generic statins (−19.1% to −13.9%). Average dose of
rosuvastatin was 12 mg vs. 17–35 mg for other statins. Among
patients not at goal at baseline, the adjusted percentage of mod-
erate/high risk patients attaining LDL-C goal was higher (p <
0.001) for rosuvastatin (76.1%) versus atorvastatin (72.6%) and
other statins (57.6%–65%). Rosuvastatin was more effective
and less costly than atorvastatin in terms of cost per patient
reaching goal (in high and moderate risk patients) and in terms
of percent LDL-C lowering. Simvastatin and pravastatin
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required a discount greater than 61% and 71%, respectively,
from the branded WAC to achieve cost per unit of LDL-C reduc-
tion lower than generic lovastatin. CONCLUSION: To facilitate
effective and efﬁcient management of patients with dyslipidemia,
a tiered formulary could include generic simvastatin or pravas-
tatin as the cost-effective generic statin in the ﬁrst tier (depend-
ing upon level of discount to current WAC) and rosuvastatin as
the cost-effective branded statin in the second tier.
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OBJECTIVES: Clinical evidence suggests that achieving recom-
mended HDL-C levels reduces the likelihood of CHD events and
mortality. The beneﬁts of standard fenoﬁbrate formulation 
on HDL-C and triglyceride levels (TG) are well established;
however, full beneﬁts have typically required administration with
food. Furthermore, evidence suggests that as many as 30% of
people do not comply with food requirements. A new formula-
tion of fenoﬁbrate (fenoﬁbrate 145) that does not require admin-
istration with food has been developed. A cost-effectiveness
model was developed to determine the incremental cost of
meeting additional recommended lipid levels when fenoﬁbrate
145 is substituted for a standard fenoﬁbrate formulation 
that requires food administration in a diabetic population.
METHODS: A simulation model using a managed care per-
spective was designed to predict changes in lipid levels [HDL-C,
LDL-C, TG, and total cholesterol (TC)] and associated drug
costs based on Wholesale Acquisition Costs over the course of
1 year. Lipid targets were based on NCEP-ATP III. A hypothet-
ical cohort of 1000 was modeled for a diabetic population with
abnormal lipid levels based on NHANES data. Lipid changes
were based on the study of fenoﬁbrate by Athyros, et al. 2002.
A reduction in efﬁcacy for each lipid parameter, based on previ-
ously reported work, was applied against patients on standard
fenoﬁbrate therapy (requiring food co-administration).
RESULTS: In a cohort of 1000 patients, substituting fenoﬁbrate
145 for standard fenoﬁbrate therapy resulted in 9.4% more dia-
betic patients reaching TG targets. Seventy-two more patients
(11% increase) on fenoﬁbrate 145 achieved at least 2 targets and
27 more patients (18% increase) achieved at least 3 targets. The
incremental 1 year cost per additional patient reaching TG
targets was $0.78. CONCLUSION: Substituting a non-food
requiring fenoﬁbrate for a standard fenoﬁbrate increases the
number of patients achieving TG and multiple target goals at 1
year at a low cost.
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OBJECTIVES: Previous studies have examined the association
between depression and hypertension. This study aims to
examine whether health status and health care costs differ
between hypertensive patients with and without depression.
METHODS: The study sample was all adult survey respondents
with a self-reported diagnosis of hypertension from the MEPS
(2002–2003). These respondents were also asked about the pres-
ence of conditions related to depression. Health status measures
include SF-12 physical component summary (PCS) and SF-12
mental component summary (MCS) score, and EQ-5D utility
score. Health care utilization was explored in the following cat-
egories: outpatient, inpatient, dental, and pharmacy. The impact
of depression on health status or health care utilization was
explored using multivariate linear regression models with depres-
sion as an independent dummy variable, after controlling for age,
gender, ethnicity, marital status, income, and health insurance.
All analyses are weighted to the US population by the personal
level weights reported in the MEPS data set. RESULTS: Among
a total of 5052 MEPS respondents having hypertension, 1962
reported having (38.84%) depression problems. These two
groups (with and without depression) were comparable in age
and ethnicity. Female hypertensive patients with lower income
level or with Medicare or Medicaid coverage had a higher 
proportion of depression. In regression models, hypertensive
patients with depression had worse health status: SF-12 PCS
score (−5.6, p < 0.0001), SF-12 MCS score (−13.5, p < 0.0001),
and EQ-5D utility score (−0.20, p < 0.0001). Hypertensive
patients with depression had higher utilization of outpatient
($415, p < 0.0001) and pharmacy ($10, p < 0.0001) services, but
both groups had comparable expenditures in inpatient care
($0.09, p < 0.0001) and dental service (−$23, p > 0.05). CON-
CLUSION: In the U.S. population, hypertensive patients with
depression had poorer health status and higher health care
expenditure in outpatient services and prescription drug com-
pared with those without depression. The difference in inpatient
cost between these groups was very small.
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OBJECTIVES: Using recent US national claims data, this study
examined characteristics of managed care patients taking clopi-
dogrel in outpatient settings and analyzed patterns of use.
METHODS: This retrospective study identiﬁed patients with
oral antiplatelet claims in a large, national, managed care claims
database (Pharmetrics) between 1/2003–6/2006 (n = 47,364). All
medical and pharmacy claims were analyzed during this period.
Analysis focused on outpatient use patterns of clopidogrel and
patient characteristics, e.g., demographics, comorbidities, inpa-
tient history, and other cardiovascular medication use. Aspirin
therapy was not available in the prescription claims data.
RESULTS: Clopidogrel was the most widely prescribed
antiplatelet, representing 93% of all prescriptions. Men repre-
sented 65% of the patients taking clopidogrel. The mean age was
56.9 years, with 69% of individuals aged 50 to 65 years. The
most common outpatient diagnoses were essential hypertension
(61%), unspeciﬁed hyperlipidemia (57%), hypercholesterolemia
(44%), and unspeciﬁed chest pain (43%). On average, users of
clopidogrel had 3.41 prescriptions per month in 2006 at a health
plan cost of $376.50/month. Average length of therapy for clopi-
dogrel was 292 days. By patient type, it varied from 283 days
for coronary artery bypass surgery, 336 days for percutaneous
coronary intervention (PCI), and 344 days for stroke. However,
10.4% of PCI patients took clopidogrel for ≤30 days. Patients
reﬁlled their clopidogrel prescriptions for 93% of the daily
regimen needed during therapy. Frequent concomitant cardiac
medications included statins (63.9%), beta-blockers (55.0%),
ACE-inhibitors (48.7%), and diuretics (14.2%). Data show that
40–50% of patients discontinued another concomitant cardiac
